Lpl Financial LLC Adma Biologics, Inc. Transaction History

Lpl Financial LLC

$320 Billion
Q3 2025

A detailed history of Lpl Financial LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 202,781 shares of ADMA stock, worth $3.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

202,781

Previous 215,182 5.76%

Holding current value

$3.16 Million

Previous $3.92 Million 24.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$14.66 - $19.91 $181,798 - $246,903	-12,401 Reduced 5.76%	202,781 $2.97 Million
Q2 2025 Aug 12, 2025	BUY	$17.6 - $24.51 $1.85 Million - $2.57 Million	104,929 Added 95.17%	215,182 $3.92 Million
Q1 2025 May 07, 2025	BUY	$15.44 - $20.61 $780,723 - $1.04 Million	50,565 Added 84.72%	110,253 $2.19 Million
Q4 2024 Feb 11, 2025	SELL	$15.62 - $22.62 $8,138 - $11,785	-521 Reduced 0.87%	59,688 $1.02 Million
Q3 2024 Nov 08, 2024	BUY	$11.21 - $20.03 $119,532 - $213,579	10,663 Added 21.52%	60,209 $1.2 Million

Q2 2024 Aug 07, 2024	BUY	$5.98 - $11.18 $197,232 - $368,738	32,982 Added 199.12%	49,546 $553,000
Q1 2024 May 10, 2024	BUY	$4.4 - $6.74 $20,328 - $31,138	4,620 Added 38.68%	16,564 $109,000
Q4 2023 Feb 14, 2024	BUY	$3.08 - $4.52 $218 - $320	71 Added 0.6%	11,944 $53,000
Q3 2023 Nov 13, 2023	BUY	$3.47 - $4.61 $2,210 - $2,936	637 Added 5.67%	11,873 $42,000
Q2 2023 Jul 31, 2023	SELL	$3.12 - $4.22 $36,369 - $49,192	-11,657 Reduced 50.92%	11,236 $41,000
Q1 2023 May 10, 2023	BUY	$3.01 - $3.87 $5,336 - $6,861	1,773 Added 8.39%	22,893 $75,000
Q4 2022 Feb 07, 2023	BUY	$2.47 - $3.88 $52,166 - $81,945	21,120 New	21,120 $81,000

Others Institutions Holding ADMA

# of Institutions

400

Shares Held

205M

Call Options Held

3.06M

Put Options Held

1.88M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.06B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Adma Biologics, Inc. Transaction History